Article

Associations of DMT Therapies with COVID-19 Severity in Multiple Sclerosis: An International Cohort Study

2020-10-15

Abstract excerpt

Background: People with multiple sclerosis (MS) may be a vulnerable group for severe COVID-19, particularly those taking immunosuppressive disease-modifying therapies (DMTs).Objectives: To examine characteristics of COVID-19 severity in an international sample of people with MS.<br><br>Methods: Clinician and patient-reported data from 82 countries were aggregated into two datasets of 1,625 and 7,365 patients, res...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 3d6d6cbb-9ace-5942-9ed8-2351a7bd43a8
DOI: 10.2139/ssrn.3711429

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Associations of DMT Therapies with COVID-19 Severity in Multiple Sclerosis: An International Cohort StudyDOI 10.2139/ssrn.3711429Read

Associations of DMT therapies with COVID-19 severity in multiple sclerosisSemantic proximity Read

Disease Modifying Therapies and COVID-19 Severity in Multiple SclerosisSemantic proximity Read

COVID-19 Severity in Multiple Sclerosis: Putting Data Into ContextSemantic proximity Read

Increased Rate of Hospitalisation for COVID-19 Amongst Rituximab Treated Multiple Sclerosis Patients: A Study of the Swedish MS RegistrySemantic proximity Read

COVID-19 in Multiple Sclerosis Patients and Risk Factors for Severe InfectionSemantic proximity Read

COVID-19 in multiple sclerosis patients and risk factors for severe infection.Semantic proximity Read

COVID-19 OUTCOMES IN MS: EARLY EXPERIENCE FROM NYU MULTIPLE SCLEROSIS COMPREHENSIVE CARE CENTERSemantic proximity Read

SARS-CoV-2 infection among patients with multiple sclerosis; A cross-sectional studySemantic proximity Read

COVID-19 Outcomes Among Users of CD20 Inhibitors for Immune-Mediated Diseases: A Comparative Cohort StudySemantic proximity Read

Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune modifying therapies: a nationwide cohort study in the OpenSAFELY platformSemantic proximity Read

Impact of mass vaccination on SARS-CoV-2 infections among the total multiple sclerosis population receiving immunomodulatory disease-modifying therapies in EnglandSemantic proximity Read

Serious infections in patients with relapsing and progressive forms of multiple sclerosis: A German claims data study.Semantic proximity Read